NCT06339658 ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
| NCT ID | NCT06339658 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital Universitari de Bellvitge |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 43 participants |
| Start Date | 2021-01-01 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 43 participants in total. It began in 2021-01-01 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.
Eligibility Criteria
Inclusion Criteria: * Breast cancer cN+ patients who undergo neadjuvant treatment. Exclusion Criteria: * Patients in whom there is a contraindication for the use of ICG. * Patients in whom there is evidence of progression of the disease after neoadjuvant treatment.
Contact & Investigator
Carlos Ortega-Expósito
PRINCIPAL INVESTIGATOR
Hospital Universitari de Bellvitge
Frequently Asked Questions
Who can join the NCT06339658 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06339658 currently recruiting?
Yes, NCT06339658 is actively recruiting participants. Contact the research team at agarciat@bellvitgehospital.cat for enrollment information.
Where is the NCT06339658 trial being conducted?
This trial is being conducted at L'Hospitalet de Llobregat, Spain.
Who is sponsoring the NCT06339658 clinical trial?
NCT06339658 is sponsored by Hospital Universitari de Bellvitge. The principal investigator is Carlos Ortega-Expósito at Hospital Universitari de Bellvitge. The trial plans to enroll 43 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.